HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Humacyte, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $406.00K | $493.00K | $439.00K | $703.00K | $100.00K | $147.00K | $0 | $0 | $0 | $0 | 100.0% | +306.0% |
| Contract Revenue [Member] | $0 | $2.00K | $28.00K | $50.00K | $201.00K | $370.00K | $0 | $0 | $0 | $0 | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Humacyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.